EP0572417A1 - Amplification d'acides nucleiques par replication bi-enzymatique auto-entretenue de sequences - Google Patents

Amplification d'acides nucleiques par replication bi-enzymatique auto-entretenue de sequences

Info

Publication number
EP0572417A1
EP0572417A1 EP92901557A EP92901557A EP0572417A1 EP 0572417 A1 EP0572417 A1 EP 0572417A1 EP 92901557 A EP92901557 A EP 92901557A EP 92901557 A EP92901557 A EP 92901557A EP 0572417 A1 EP0572417 A1 EP 0572417A1
Authority
EP
European Patent Office
Prior art keywords
subsegment
dna
segment
target
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP92901557A
Other languages
German (de)
English (en)
Other versions
EP0572417A4 (fr
Inventor
Eoin David Fahy
Deborah Yantis Kwoh
Thomas Raymond Gingeras
John Christopher Guatelli
Kristina Marie Whitfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Siska Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV, Siska Diagnostics Inc filed Critical Akzo Nobel NV
Publication of EP0572417A1 publication Critical patent/EP0572417A1/fr
Publication of EP0572417A4 publication Critical patent/EP0572417A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]

Definitions

  • the present invention relates generally to methods and kits for amplifying target nucleic acid segments in samples of nucleic acids.
  • the invention also concerns applications of the methods and kits in
  • nucleic acid sequence i.e., a nucleic acid segment with a particular sequence
  • a fundamental problem in such work is to detect or isolate, and if possible quantitate, a particular nucleic acid sequence of interest in such a background.
  • the problem has been a difficult one because biological materials, such as cell cultures, tissue specimens and blood
  • RNAs and DNAs typically are comprised of a complex mixture of RNAs and DNAs, of which at most only a minuscule fraction has a segment of interest.
  • target segment a nucleic acid segment of interest
  • the amount of nucleic acid (including the target segment) in a sample of nucleic acid subjected to analysis is not altered;
  • a signal-generating system is associated with the target segment and produces a detectable signal representative of the presence or the number of copies of target segment in the sample.
  • a nucleic acid probe with a sequence complementary of that of at least a subsegment of the target segment and linked to an enzyme, such as alkaline phosphatase, is mixed with sample under hybridization conditions, that effect hybridization between the probe and target segment but not appreciably between probe and other nucleic acid segments in the sample.
  • a substrate for the enzyme e.g., a
  • chromogenic substrate for alkaline phosphatase is added under conditions which allow catalysis by the enzyme to proceed and, in principle, a large number of detectable molecules is rapidly produced in the enzyme-catalyzed reaction (visibly colored in the case of a chromogenic substrate with alkaline phosphatase) for each probe molecule hybridized to target segment.
  • target nucleic acid segments have been detected on the basis of hybridization with a probe labelled with a radioactive isotope (e.g., 32 P) or a fluorescent moiety.
  • a probe which comprises or is linked to an autocatalytically replicatable RNA molecule (e.g., an RNA that is a substrate for the
  • RNA-dependent RNA polymerase of Q ⁇ phage or brome mosaic virus BMV, see Miele et al., J. Mol. Biol. 171, 281
  • probe for a target segment is linked to a RNA capable of being replicated by Q ⁇ replicase is described by Chu et al., Nucl. Acids Res. 14, 5591 (1986) and United States Patent No. 4,957,858 and by BMV replicase by Marsh et al.,
  • the copy number of target segment in a sample of practical size is so low that, even for reasonably rapid signal-generating systems, the time required to generate detectable signal that is significantly above background is impracticably long.
  • signal-generating molecules e.g., probe molecules hybridized to segments with sequences nearly the same but not identical to the sequence of target segment, probe molecules adhering to glass, plastic or other components of a system, etc.
  • signal-generating molecules e.g., probe molecules hybridized to segments with sequences nearly the same but not identical to the sequence of target segment, probe molecules adhering to glass, plastic or other components of a system, etc.
  • the sensitivity of assays using the first approach is fundamentally limited by unavoidable "background" signal-generating molecules.
  • the second approach is fundamentally different. It involves increasing the copy number of the target segment itself, preferably to an extent greater than that of other segments in a sample, particularly those that might erroneously be detected as target segments because of similarities in sequences.
  • Examples of this second approach include various culture techniques in which cells that harbor the target segment are caused to increase in number,
  • nucleic acids e.g., plasmids, RNAs
  • target segment e.g., plasmids, RNAs
  • Another example of this second approach is amplification of a DNA target segment in a so-called
  • PCR polymerase chain reaction
  • a DNA primer complementary to that of target segment
  • a DNA primer (2) extending each of the primers with a DNA polymerase, and (3) rendering single-stranded by thermal denaturation the duplexes resulting from step (2).
  • the PCR technique is described in Saiki et al., Science 230, 135 (1985) and Mullis et al., European Patent Application Publication Nos. 0 200 362 and 0 201 184 and US Patent Nos. 4,683,195 and 4,683,202.
  • Another technique for carrying out the second approach to detecting a target segment present at a low level in a complex mixture of nucleic acids is by
  • TAS transcription-based amplification system
  • TAS employs an RNA-transcript-production step from a DNA synthesized to incorporate a segment with the sequence of target and a promoter positioned, with respect to the target-sequence-containing segment, to enable transcription from the segment of a RNA with the sequence complementary to that of target. Multiple cycles can be carried out, as the RNA made in the transcription step can serve as template for making similarly transcribable DNA, which, in turn, can be transcribed to yield additional RNA.
  • Amplification proceeds very rapidly with each cycle, as between about 10 and about 1,000 copies of RNA comprising the sequence of target segment or the sequence complementary thereto are produced rapidly from each double-stranded DNA which incorporates a promoter driving transcription of a segment comprising target segment.
  • the TAS method is described in commonly owned United States Patent
  • amplification provides a rapid increase in copy number of a selected target segment by making use of two properties of DNA-dependent RNA polymerases: (1) appreciable initiation of transcription from only a small number of sequences specific for each polymerase, see, e.g., Brom et al., Nucl. Acids Res. 14, 3521 (1986); and (2) rapid production of a large number of transcripts (typically 10 2 -10 4 per hour) from each copy of a promoter recognized by an RNA polymerase. See Milligan et al., Nucl. Acids Res. 15, 8783 (1987).
  • use of the TAS system makes possible unambiguous measurement of the amount of target nucleic acid segment present in a sample.
  • the TAS method utilizes RNA-dependent DNA polymerase activity and DNA-dependent DNA polymerase activity, both of which can be provided by a reverse transcriptase, as well as DNA-dependent RNA polymerase activity and primers.
  • the primers define the ends of the target segment to be amplified. At least one of the primers, typically that which hybridizes to the 3'-end of the target segment, includes a segment which has the sequence of the sense strand of a promoter and is
  • promoters employed in the TAS method are those recognized by the RNA polymerases of T7 phage, T3 phage, and SP6 phage.
  • the TAS method can be employed to amplify an RNA target segment.
  • the primers are employed to make from the RNA comprising the target segment a double stranded DNA which incorporates a promoter driving transcription of a DNA which comprises a segment with the sequence of target segment, to yield RNA comprising a segment with the sequence complementary to that target segment.
  • the TAS method can also be employed to amplify a target segment of a double-stranded nucleic acid.
  • the double-stranded nucleic acid of a sample is denatured and the primers are allowed to hybridize to their respective strands, one primer (the "antisense” primer) hybridizing to the 3'-end of target segment and the other (the “sense” primer) to the 3'-end of the complement of target segment.
  • the primers are then extended with a suitable polymerase and the resulting duplexes are thermally denatured and cooled to allow the respective primers to hybridize again, to not only the strands of double-stranded sample nucleic acid which comprise target segment but also to the extension products made in the initial primer extension reaction.
  • the hybridized primers are again extended in a reaction catalyzed by a suitable polymerase and, with the primers hybridized to extension products of the initial primer extension, two types of double-stranded DNA are formed, at least one of which comprises a promoter operatively linked for transcription to a segment which comprises target segment.
  • the double-stranded DNAs, which comprise such promoters are transcribed by a DNA-dependent RNA polymerase which recognizes the promoter, to yield RNA comprising a segment complementary to that of target segment and, thereby, in effect, to amplify target segment itself.
  • the above process of hybridization, extension, thermal denaturation, hybridization, extension and transcription may be repeated using both the strands of the newly produced double-stranded DNAs and the resulting RNA transcripts as templates.
  • RNAs made in the process yields, inter alia, a first single-stranded RNA transcript, which comprises a segment with the sequence of either target segment or the complement thereof, and which is in large excess relative to a second RNA of sequence complementary to that of the first RNA.
  • TAS provides an abundance of single-stranded RNA which can be detected without the necessity of cumbersome, repeated PCR thermal cycling or strand separation.
  • the present invention entails the surprising discovery of a method of substantially continuous, self-sustained, target nucleic acid amplification which proceeds spontaneously and isothermally.
  • This method for self-sustained sequence replication (hereinafter "3SR") provides for amplification of an RNA target segment utilizing RNA-dependent DNA polymerase activity, DNA-dependent DNA polymerase activity, RNAse H activity and DNA-dependent RNA polymerase activity, and primers which are capable of hybridizing to the target segment or complement thereof and priming a primer extension
  • RNAse H activity obviates the need for thermal cycling by enzymatically catalyzing the digestion of an RNA strand of an RNA-DNA duplex rendering single stranded the DNA strand of said duplex which was synthesized in a primer extension reaction utilizing said RNA strand as template.
  • the four enzymatic activities may be provided by a combination of reverse transcriptase and DNA dependent RNA polymerase.
  • the present invention entails methods of 3SR
  • RNAse H activity of reverse transciptase provides the required RNAse H activity
  • methods wherein the RNAse H activity of reverse transcriptase is supplemented with another source of RNAse H activity, such as E. coli RNAse H, whereby increased levels of amplification of from about 10 5 - to 10 6 -fold may be achieved.
  • the present invention also entails the
  • reverse transcriptases have sufficient RNAse H activity to provide extremely sensitive 3SR
  • amplification reactions which are capable of amplifying an RNA target segment from about 10 5 -fold to about
  • the present invention relates to 2-enzyme 3SR methods of target nucleic acid segment amplification which enable a target nucleic acid segment to be amplified from about 10 5 -fold to about 10 9 -fold within 4 hours, typically in from 1/2 hour to 2 hours.
  • the present invention is further concerned with novel improvements in 3SR amplification methods. These improvements entail improved reaction media and other reaction conditions, which enable target segment
  • the present invention also provides methods for 2-enzyme 3SR amplification, whereby relatively large target segments, in excess of about 700 bases, may be amplified to levels otherwise achievable with only smaller target segments.
  • the present invention provides kits for
  • kits comprising improved reaction media for 3-enzyme 3SR amplification or components for 2-enzyme 3SR
  • Figure 1 is a schematic representation of an embodiment of the present invention.
  • Figure 1 depicts the process of self-sustained sequence replication (3SR) as a step-by-step process, although it will be understood that in practice all of the various steps occur
  • RNA-dependent DNA polymerase activity (RT activity 1)
  • DNA-dependent DNA polymerase activity (RT activity 2)
  • RNAse H activity (RT activity 3)
  • the darkened rectangular blocks represent promoter-providing segments of the first primer (designated “A”) and the second primer (designated “B”).
  • Figures 2a and 2b depict a detailed schematic representation of the various steps of an embodiment of the present invention which shows the various subsegments which comprise the nucleic acid species stably or
  • Self-sustained sequence replication can be made to proceed to completion because, as was discovered surprisingly, it is possible to maintain a reaction mixture, including enzymes for providing the four necessary enzymatic activities, primers, ribonucleoside triphosphates and 2'-deoxyribonucleoside triphosphates, and RNA, under reaction conditions suitable for both hybridization of primers and, at suitable levels, the four necessary enzymatic activities.
  • the 3SR method employs two DNA- primers, which prime chain-extension reactions using the target segment or complement thereof, respectively, as template. At least one of the primers includes the sense strand of a promoter. Amplification by the 3SR method, which is continuous and substantially isothermal, requires four enzymatic activities provided by at least two enzymes - reverse transcriptase (to provide RNA-dependent DNA polymerase activity and DNA-dependent DNA polymerase activity, and RNAse H activity) and a DNA-dependent RNA polymerase.
  • the RNAse H activity employed in 3SR is used to render single-stranded a DNA extension product when an RNA segment acts as template for making the extension product, unlike TAS, which requires a denaturation step.
  • the RNAse H activity of a reverse transcriptase used in the 3SR reactions of the invention may optionally be supplemented with a source of RNAse H activity other than the reverse transcriptase, such as E. coli RNAse H.
  • RNAse H is not easily isolated in acceptably pure form, and is considerably more expensive than the other two enzymes required for 3SR amplification, it is highly desirable to eliminate the requirement for an enzyme separate from a reverse transcriptase to provide an amount of RNAse H activity effective for high sensitivity amplification which is necessary to detect nucleic acid target segments present, before amplification, at very low concentrations.
  • promoters identification, isolation, sequencing or preparation of promoters, or more specifically, promoters or sites recognized by bacteriophage DNA-dependent RNA polymerases for binding preparatory to catalysis of transcription, or, in the employment of eukaryotic systems, such
  • RNA-dependent RNA polymerases for example,
  • RNA transcripts including so-called transcription enhancer sequences
  • polymerase chain reaction methods including the reagents used therein; and so forth. See, for example, Maniatis et al., Molecular Cloning: A
  • primer in the present context is meant a single-stranded nucleic acid that has a segment at its 3'-end with sufficient homology to a segment of the target segment or complement thereof such that, under suitable hybridization conditions, it is capable of hybridizing to the target segment (or complement thereof) and priming a primer extension reaction in which a nucleic acid having the sequence of the target segment (or complement thereof) is the template.
  • a hybridizing segment of a typical primer is at least about 10
  • a "primer” is preferably a DNA.
  • an "antisense primer” means a primer which has a sequence sufficiently complementary to a sequence at the 3'-end of the target segment to be extended in a chain-extension reaction using target segment as template; a “sense primer” means a primer which has a sequence similarly sufficiently homologous to a sequence at the 5'-end of such target segment.
  • the primers define the ends of the target segment to be amplified.
  • the sense and antisense primers, respectively have segments, which include at least their 3'-ends, that share identity or very high homology with the 5'-end of the target segment and the complement of the 3'-end of the target segment, respectively. See, for example, EPA 128042 (publd. 12 Dec 84).
  • At least one, optionally both, of the primers comprise a segment with a promoter sense sequence.
  • promoter sense strand is meant a single stranded nucleic acid which, when hybridized with its complement to be in its double-stranded form (i.e., as a double-stranded promoter), is specifically recognized by an RNA polymerase, which binds to a polymerase-binding sequence of the promoter and initiates the process of transcription whereby an RNA transcript is produced.
  • any sense promoter sequence may be employed for which there is a known and available polymerase that is capable of recognizing the sequence.
  • promoters are those that are recognized by certain bacteriophage RNA polymerases, such as those from bacteriophage T3, T7 or SP6. See Siebenlist et al., Cell 20, 269 (1980). These are but examples of the RNA polymerases which can be employed in the practice of the present invention in conjunction with their associated promoter sequences.
  • a "promoter sense strand,” as used herein, preferably comprises one or more
  • promoter sense sequence must be of sufficient length such that, upon completion of a cDNA incorporating said sequence, the consensus sequence of the promoter is completely double-stranded. In these cDNAs, transcription occurs from the promoter when an RNA polymerase that recognizes the promoter is present under conditions suitable for transcription from the promoter.
  • Bacteriophage promoters are preferred because of their high specificity for their cognate RNA
  • polymerases and the invention is intended to cover such other promoters and RNA polymerases as well, provided that said promoter shows a high degree of specificity for said polymerase.
  • the preferred of the bacteriophage promoter sense sequences are the (+) strands of T7, T3 and SP6 promoters which include the segment to which the
  • RNA polymerase binds and at least one, and preferably about 4 up to about 10, nucleotides 5' from the 5'-end of this polymerase-binding segment.
  • Preferred promoters and their corresponding RNA polymerases are described in the examples and claims, but numerous other promoters and RNA polymerases are known in the art and can be employed as well.
  • variable subsegments that are optionally included in the DNA primers serve one or more functions.
  • the variable subsegments preferably include transcription initiation sequences that are preferred by the RNA polymerase corresponding to the promoter. While the bacteriophage T7 transcription initiation sequence 5'-GGGA-3', which is located adjacent to the 3' end of the 17 nucleotide T7 promoter consensus sequence, is believed to be important to in vivo transcription, it does not appear to be crucial for transcription during 3SR amplification.
  • Example IX shows the effect on amplification levels caused by mutations (nucleotide changes or deletions) in the transcription initiation sequence immediately downstream from the 17 nt consensus sequence of the T7 promoter.
  • initiation sequence is optional for primers having a promoter-providing segment.
  • Such primers having the 3'-most nucleotide of the promoter consensus sequence adjoining a target hybridization segment may provide high levels of amplification comparable to those attained where the transcription initiation sequence 5'-GGGA-3' is present. It is preferred, however, to include a segment of at least one to about four, preferably four,
  • nucleotides adjoining the 3'-most nucleotide of the promoter consensus sequence are nucleotides adjoining the 3'-most nucleotide of the promoter consensus sequence.
  • An example of a preferred sequence for inclusion at the site of the transcription initiation sequence adjoining the 3'-most nucleotide of the T7 consensus sequence is the sequence 5'-GAAA-3'.
  • variable subsegment can optionally contain a particular non-target segment whereby RNA product from the amplification can be detected in a nucleic acid probe hybridization assay.
  • variable subsegment may also contain a polylinker sequence that conveniently contains a plurality of restriction sites for ease of subsequent cloning. Further, the variable subsegment may contain the sequence of a
  • RNA such as Q ⁇ virus
  • replicase e.g., Q ⁇
  • RNA replicase can multiply and autoreplicate an RNA
  • operably linked in particular in connection with the linkage of a promoter sequence of a primer to a hybridizing (anti-target or anti-target complement) sequence of said primer, refers to the functionality of the ultimate "double-stranded nucleic acid template" or "cDNA” synthesized in the amplification methods of the present invention and incorporating the primer.
  • cDNAs so produced are capable of producing RNA transcripts in the presence of a DNA-dependent RNA polymerase that recognizes the promoter, when the
  • promoter sense-strand segment of a primer is "operably linked for transcription" to the primer 3'-segment, which hybridizes to target for complement of target.
  • the primer extension reaction to produce a DNA-RNA or DNA-DNA duplex is well known. Reverse
  • transcriptases particularly from retroviruses, are known to be useful for providing DNA-dependent-DNA polymerase and RNA-dependent-DNA polymerase activity.
  • RNAse H activity an amount of RNAse H activity which, in a reaction mixture containing
  • DNA-dependent RNA polymerase and substrates therefor, and which is incubated in a temperature range at which the latter three enzymatic activities are active, is capable of amplifying said RNA target segment at least about 10 5 -fold in 2-4 hours.
  • high sensitivity amplification-effective amount of RNAse H as used herein is meant to relate to the level of amplification
  • RNAse H activity which is effective for 3SR amplification reaction may be less than a "high sensitivity amplification-effective amount" of RNAse H activity, and in such cases may be sufficient to amplify, in a 3SR amplification reaction, a target nucleic acid segment which is present at a concentration such that the level of amplification needed for detection is less than about 10 2 -fold to about 10 4 -fold.
  • RNAse H activity known to be possessed by retroviral reverse transcriptases is known under certain conditions, to digest the RNA strand of an RNA-DNA duplex into small oligonucleotides (e.g., oligoribonucleotides of less than about 5-10 bases in length) while leaving the DNA strand intact.
  • small oligonucleotides e.g., oligoribonucleotides of less than about 5-10 bases in length
  • nucleic acid hybridization necessary for detection, by nucleic acid hybridization, of a nucleic acid target segment present at a
  • rNTPs The four ribonucleoside triphosphates, rATP, rUTP, rCTP and rGTP, are referred to collectively herein as "rNTPs" or "rXTPs.”
  • the invention entails a method for 3SR amplification of a target RNA segment of a target RNA molecule which segment comprises a
  • 5'-subsegment which includes a 5'-terminal nucleotide and extends at least 9 nucleotides in the 3'-direction from the 5'-terminal nucleotide of the target segment, and a 3'-subsegment, which does not overlap the
  • step 1 which method comprises incubating in a reaction medium:
  • a first DNA primer which is a single stranded DNA which comprises at its 3'-end a first subsegment having a 3'-terminal nucleotide and extending at least 9 nucleotides in the 5'-direction, said first subsegment of said first primer being of the same length as the 3'-subsegment of the target segment and having a sequence sufficiently complementary to that of the
  • 3'-subsegment of the target segment to prime, in the reaction medium, a primer extension reaction in which a nucleic acid with the sequence of the target segment is the template, and (2) a second DNA primer, which is a single-stranded DNA which comprises at its 3'-end a first subsegment having a 3'-terminal nucleotide and extending at least 9 nucleotides in the 5'-direction, said first subsegment of said second primer being of the same length as the 5'-subsegment of the target segment and having a sequence sufficiently homologous to that of the
  • a primer extension reaction in which a nucleic acid with the sequence complementary to that of the target segment is the template, provided that at least one of said primers further comprises a
  • promoter-providing subsegment which comprises the sense strand of a first promoter, said sense strand being joined to the first subsegment of the primer, which comprises said promoter-providing segment, operably for transcription from said first promoter of a cDNA
  • 5'-terminal nucleotide of said 5'-subsegment of said target RNA segment is the 5'-terminal nucleotide of the target RNA molecule
  • RNA-dependent DNA polymerase and DNA-dependent RNA polymerase activities
  • said incubation occurs in a range of temperatures at which said enzymes in said reaction medium are active in providing said DNA-dependent DNA polymerase, RNA-dependent DNA polymerase, RNAse H, and DNA-dependent RNA polymerase activities.
  • the invention entails a method for highly sensitive, highly productive, 2-enzyme 3SR amplification of a target RNA segment of a target RNA molecule which segment comprises a
  • 5'-subsegment which includes a 5'-terminal nucleotide and extends at least 9 nucleotides in the 3'-direction from the 5'-terminal nucleotide of the target segment, and a 3'-subsegment, which does not overlap the
  • step 1 which method comprises incubating in a reaction medium:
  • a first DNA primer which is a single stranded DNA which comprises at its 3'-end a first subsegment having a 3'-terminal nucleotide and extending at least 9 nucleotides in the 5 '-direction, said first subsegment of said first primer being of the same length as the 3'-subsegment of the target segment and having a sequence sufficiently complementary to that of the
  • 3'-subsegment of the target segment to prime, in the reaction medium, a primer extension reaction in which a nucleic acid with the sequence of the target segment is the template, and (2) a second DNA primer, which is a single-stranded DNA which comprises at its 3'-end a first subsegment having a 3'-terminal nucleotide and extending at least 9 nucleotides in the 5'-direction, said first subsegment of said second primer being of the same length as the 5'-subsegment of the target segment and having a sequence sufficiently homologous to that of the
  • a primer extension reaction in which a nucleic acid with the sequence complementary to that of the target segment is the template, provided that at least one of said primers further comprises a
  • promoter-providing subsegment which comprises the sense strand of a first promoter, said sense strand being joined to the first subsegment of the primer, which comprises said promoter-providing segment, operably for transcription from said first promoter of a cDNA
  • 5'-terminal nucleotide of said 5'-subsegment of said target RNA segment is the 5'-terminal nucleotide of the target RNA molecule
  • RNA-dependent DNA polymerase and DNA-dependent RNA polymerase activities
  • said incubation occurs in a range of temperatures at which said enzymes in said reaction medium are active in providing said DNA-dependent DNA polymerase, RNA-dependent DNA polymerase, RNAse H, and DNA-dependent RNA polymerase activities.
  • 3SR amplification methods require at least one promoter-providing primer, which is a primer which comprises a segment with the sense sequence of a
  • the first primer and the second primer are also referred to herein as the
  • antisense primer and “sense primer,” respectively.
  • the antisense primer is the preferred primer to include a promoter sequence, although as will become clear from the description of the present invention, the antisense and the sense primers may each include a promoter sequence, and in certain instances, amplification may proceed where only the sense primer includes such a promoter sequence.
  • segment is a DNA (d) sequence which is complementary (c) to the segment designated hereinafter as (3'-subsegment tcd ) is a DNA (d) sequence which is complementary (c) to the segment designated hereinafter as (3'-subsegment tcd ) is a DNA (d) sequence which is complementary (c) to the segment designated hereinafter as (3'-subsegment tcd ) is a DNA (d) sequence which is complementary (c) to the
  • 3'-subsegment i.e., primer hybridizing segment of the RNA target (t) segment, which hybridizing segment is designated (3'-subsegment tr ).
  • RNA target segment in the reaction medium. Also described thereafter is the production of an RNA target segment from a double-stranded DNA, which includes a segment with the same sequence as the target RNA segment (substituting ribonucleotides for 2'-deoxyribunucleotides and U for T), for situations where a target RNA segment may not be present initially in a biological sample or other sample of nucleic acid to which the method of the invention is to be applied.
  • 2-enzyme 3SR amplification in accordance with the present invention, is initiated with a target RNA segment of Formula I:
  • the subsegment designated (5'-subsegment tr ) is an RNA segment of known sequence having at least 10 nucleotides, including the 5'-most nucleotide of the RNA target segment and extending in the 3' direction therefrom at least 9 nucleotides.
  • the (3'-subsegment tr ) is an RNA segment of known sequence of at least 10 nucleotides, including the 3 '-most nucleotide of the RNA target segment and extending in the 5' direction therefrom at least 9 nucleotides.
  • the (intermediate subsegment tr ) is an RNA segment of 0 or more nucleotides which adjoins the (3'-subsegment tr ) and the (5'-subsegment tr ). If
  • the first step in the 3SR amplification process involves hybridization of the first (antisense) primer to the 3'-subsegment of the RNA target (3'-subsegment tr ) and extension thereof by the RNA-dependent DNA polymerase activity of a reverse transcriptase using the target RNA as a template to form a DNA-RNA duplex.
  • the so-formed DNA-RNA duplex extends at least to the 5'-terminal nucleotide of the (5'-subsegment tr ). See Figure 2a, step 3.
  • the first primer is a single-stranded DNA which comprises the nucleic acid segment of Formula II:
  • the segment designated (promoter 1d ) is a single-stranded DNA segment with the sequence of the sense strand of a first promoter, preferably one recognized by a
  • (3'-subsegment tcd ) is a single-stranded DNA segment having the same number of nucleotides as, and a sequence which is sufficiently complementary to, (3'-subsegment tr ) to hybridize to and prime an extension reaction using the target RNA as template;
  • (variable subsegment 1d ) is a single-stranded DNA segment of 0 to 50 nucleotides adjoining the 3'-terminal nucleotide of (promoter 1d ).
  • subsegment 1d may comprise, for example, a native
  • transcription-initiation segment recognized by the RNA polymerase which recognizes the promoter; in the case of bacteriophage T7 polymerase, this native transcription- initiation segment would have the sequence 5'-GGGA-3'.
  • a presently preferred transcription initiation segment comprises the sequence 5'-GAAA-3'.
  • the improved reaction media of the present invention enable the 2-enzyme 3SR amplification methods of the present invention because such reaction media enable the expression of inherent RNAse H activity of reverse transcriptase.
  • This RNAse H activity of reverse transcriptase degrades the RNA strand of a DNA-RNA duplex yielding a first complementary DNA strand comprising the DNA segment of Formula III.
  • the segments (promoter 1d ), (variable subsegment 1d ) and (3'-subsegment tcd ) are defined in Formula II.
  • DNA-RNA duplex may include a DNA-RNA duplex segment which extends (relative to the RNA strand) in the 5'-direction beyond the
  • a second DNA primer hybridizes to the single-stranded first complementary DNA and primes a primer extension reaction on this first complementary DNA.
  • the second DNA primer is a single-stranded DNA comprising a sequence of at least 10 nucleotides and corresponds to Formula IV (promoter-less primer) or
  • the segment designated (5'-subsegment td ) is a DNA with a sequence which is sufficiently homologous to the sequence of (5'-subsegment tr ) to hybridize to a first complementary DNA (at (5'-subsegment tcd )) and prime a primer extension reaction using a first complementary DNA of Formula III as template.
  • the segment designated (variable) is a DNA with a sequence which is sufficiently homologous to the sequence of (5'-subsegment tr ) to hybridize to a first complementary DNA (at (5'-subsegment tcd )) and prime a primer extension reaction using a first complementary DNA of Formula III as template.
  • subsegment 2d is a segment of 0 to 100 nucleotides which adjoins the 5'-terminus of (5'-subsegment td ).
  • the second promoter sense sequence is designated (promoter 2d ).
  • segment designated (variable subsegment 1d ) is a segment of 0 to 100 nucleotides which adjoins the 5'-terminus of (5'-subsegment td ).
  • the second promoter sense sequence may be the same or different from the first promoter sequence.
  • the reaction medium may optionally include a second DNA-dependent RNA polymerase which recognizes the second promoter.
  • segment designated is an optional segment of a promoter-less sense primer of Formula IV (although it will be
  • the DNA-dependent DNA polymerase activity of reverse transcriptase extends the second primer using the first complementary DNA as a template to form a first double stranded cDNA (hereinafter cDNA I) which comprises a promoter operatively linked for transcription to a cDNA segment that is the complement of the RNA target segment (i.e., has the sequence exactly complementary to that of the target segment). See Figure 2a, step 6.
  • the cDNA comprises the first complementary DNA strand, as defined above in Formula III, and second complementary DNA strand comprising the DNA of Formula V or V(a):
  • V(a) The segments (intermediate subsegment td ),
  • promoter 1cd are segments which are complementary to (intermediate subsegment tcd ), (3'-subsegment tcd ), (variable subsegment 1d ) and (promoter 1d ), respectively.
  • the segments (promoter 2d ), (variable subsegment 2d ) and (5'-subsegment td ) are defined as in Formulae IV and IV(a);
  • cDNA I consisting of the first and second complementary DNA strands is transcribed from the first promoter in the presence of corresponding DNA-dependent RNA polymerase to produce multiple copies of an RNA transcript of Formula VI or Formula VI (a) (See Figure 2b, step 7) :
  • the segment (variable subsegment 1r ) is an RNA segment corresponding to (variable subsegment 1d ); the segments (3'-subsegment tcr ), (intermediate subsegment tcr ),
  • promoter 2cr are complementary to (3'-subsegment tr ),
  • RNA transcript of Formula VI or VI (a) is capable of
  • a first primer of Formula II hybridizes with this third complementary DNA strand and is extended to form a fourth complementary DNA. See Figure 2b, step 12.
  • the fourth complementary DNA is a segment of Formula VIII:
  • Each of the segments is defined in Formula III above.
  • the overhanging end of the fourth complementary DNA, the promoter-encoding sequence acts as a template for extension of the third complementary DNA to complete a cDNA II, Formula X, which consists of a third
  • transcripts where only the antisense primer contains a promoter sense strand
  • both sense and antisense transcripts where each primer contains a promoter sense strand
  • Sense transcripts are of Formula IX: 5'-(variable subsegment 2r )-(5'-subsegment tr )-(intermediate subsegment tr )-(3'-subsegment tr )-(variable subsegment 1cr )- (promoter1 cr )-3' IX
  • the segments designated (5'-subsegment tr ), (intermediate subsegment tr ) and (3'-subsegment tr ) are identical to or substantially homologous to the RNA target segment of Formula I.
  • the segments (variable subsegment 1cr ) and (promoter 1cr ), respectively, are the RNA sequences
  • the antisense transcripts reenter the antisense amplification loop as template to produce additional copies of cDNA II.
  • Figure 2b steps 7-12.
  • the sense transcripts of Formula IX enter a discrete sense amplification loop analogous to the just-described antisense loop. Briefly, each of the multiple copies of the sense transcript is capable of hybridizing with first primer of Formula II and
  • a second primer of Formula IV(a) hybridizes therewith and is extended to form a double stranded cDNA II which is identical to the cDNA II which consists of DNA strands of Formulae VII (a) and VIII (a).
  • cDNA II has a completely double stranded promoter at each of its ends.
  • Transcription may proceed from each of the two DNA strands, to produce multiple copies of sense transcripts (i.e., transcripts comprising a segment with sequence of target segments) and antisense transcripts (i.e., transcripts comprising segment with the sequence complementary to that of targe segment) to feed the two complementary amplification loops.
  • sense transcripts i.e., transcripts comprising a segment with sequence of target segments
  • antisense transcripts i.e., transcripts comprising segment with the sequence complementary to that of targe segment
  • RNA containing a target segment may be amplified within 2 hours to 10 6 copies or more of an RNA transcript having a segment with the sequence of the target segment or the complement thereof without the need for thermal cycling or the repeated addition of enzymes.
  • the 3SR reaction of the present invention carried out in the improved reaction media of the present invention, requires only two enzymes, reverse transcriptase and
  • DNA-dependent RNA polymerase to provide the necessary four enzyme activities.
  • RNA target molecule should not extend in the 5'-direction beyond the 5'-nucleotide of the RNA target segment (i.e., the 5'-nucleotide of the subsegment designated (5'-subsegment tr ) should be the 5'-nucleotide of the target molecule).
  • nucleotide of the target segment is the 5'-terminal nucleotide of the entire target RNA molecule
  • transcripts produced will be sense transcripts which will directly enter the amplification loop depicted by steps 7a-12. No antisense transcripts will be produced.
  • One way to ensure that the 5'-terminal nucleotide of the RNA target molecule is the 5'-terminal nucleotide of the RNA target segment is to amplify an RNA target segment of predetermined nucleic acid sequence which segment is at the 5'-end of the RNA target
  • a suitable sequence for the promoter-providing sense primer may be provided:
  • a suitable sense primer may comprise a DNA segment which includes a promoter sense strand
  • the antisense primer may consist of a DNA segment having a sequence which is complementary to a segment at the 3'-end of the target segment.
  • a second way to provide an RNA segment meeting the limitation that the 5'-terminal nucleotide of the target RNA molecule is the 5'-terminal nucleotide of the target segment is to produce such an RNA target molecule, from a DNA segment which encodes the target sequence, by conducting a cycle of TAS amplification.
  • An appropriate target RNA segment thus may be generated from a double stranded DNA (or single stranded DNA or RNA) known to encode the target sequence.
  • the first and second DNA primers are added to the reaction solution and the solution is heated at about 94oC - 100oC for 1 minute and is then cooled to 42oC over the course of 1 minute. This heating and then holding at 42oC, in combination with the composition of the solution, provides conditions of stringency sufficient to provide hybridization of the first primer and the second primer to the two complementary strands of said double-stranded DNA, with sufficient stability to prime a primer
  • DNA-dependent DNA polymerase (and the necessary nucleoside triphosphates, if not previously added) is added to polymerize the extension reaction.
  • the nucleic acid containing solution is again heated to 100°C for 1 minute and cooled to 42° for 1 minute during which step first and second primers
  • the target RNA segment provided by such a cycle of TAS amplification has its 5'-end and 3'-end defined by the two primers utilized. Such an RNA therefore
  • RNA target molecule satisfies the requirement that the 5'-terminal nucleotide of the RNA target molecule is the 5'-terminal nucleotide of the 5'-subsegment of the target RNA. It should also be clear, however, that such a cycle of TAS amplification may virtually always be used to produce an RNA target segment suitable for 3SR amplification, without regard to which primer(s) include(s) a promoter sequence. See Example II.
  • the amplifiable target segment of a nucleic acid of interest has an (intermediate subsegment tr ) including at least 20, and more preferably at least about 50, nucleotides to permit, optionally, the use of a second round of 3SR amplification using third and fourth DNA primers to amplify the (intermediate subsegment tr )) in a further refinement of the amplification method.
  • the (intermediate subsegment tr ) may be used for detecting 3SR-produced transcripts by a nucleic acid hybridization assay, where the (variable subsegment) does not have a non-target segment which may be used for this purpose.
  • the present invention involves the discovery that two enzymes, a retroviral reverse transcriptase and a DNA-dependent RNA polymerase by themselves and in the absence of an
  • RNAse H activity amplification effective amount of RNAse H activity.
  • activity of the reverse transcriptase entails carrying out the reaction in a reaction medium comprising about 20 to 40 mM of a magnesium-containing salt such as magnesium chloride, magnesium sulfate and the like; about 1 to 25 mM of an alkali metal chloride such as KCl or NaCl and the like; about 0 to 20 mM of a sulfhydryl reducing agent such as dithiothreitol (DTT), beta mercaptoethanol and the like; about 0 to 10 mM spermidine; about 1 to 8 mM ribonucleoside triphosphates; about 1 ⁇ M to 8 mM
  • a magnesium-containing salt such as magnesium chloride, magnesium sulfate and the like
  • an alkali metal chloride such as KCl or NaCl and the like
  • a sulfhydryl reducing agent such as dithiothreitol (DTT), beta mercaptoethanol and the like
  • DTT di
  • Preferred reaction media comprise:
  • reaction medium 0 - 15% dimethylsulfoxide (by volume) and an appropriate buffer (Tris, HEPES, etc.) such that said reaction medium has a pH of between about 7.5 and about 8.5, preferably pH 8.1.
  • Tris, HEPES, etc. Tris, HEPES, etc.
  • the DMSO is required when AMV reverse transcriptase is the source of RNAse H activity.
  • 3SR reactions were believed to be unsupportable using as a source of the four required enzymatic activities only a retroviral reverse transcriptase, such as AMV reverse transcriptase, and DNA-dependent RNA polymerase, where amplification levels greater than about 10 3 were desired. It has been found by the inventors that improved reaction media, surprisingly, allows the inherent RNAse H activity of retroviral reverse transcriptases to function to support such levels of 3SR amplification even in the absence of other sources of RNase H activity, such as E. coli
  • Hydroxyl containing compounds include, but are not limited to C 1 -C 10 alcohols such as methanol, ethanol, propanol, isopropanol,
  • glycols such as ethylene glycol, diethylene glycol, triethylene glycol and polyethylene glycols having an average molecular weight of up to about 20,000 daltons which are aqueous soluble
  • mono-, di- and trisaccharides such as glucose, galactose, mannose, fructose, sucrose, maltose, raffinose and the like
  • sugar alcohols such as sorbitol, glycerol, glucitol, mannitol, inositol and the like.
  • the improved reaction media of the present invention therefore preferably include one or more of the following compounds: (i) a C1-C10 alcohol; (ii) a
  • Preferred compounds of the above-defined formulae include ethanol, glycerol, sorbitol, sucrose and PEG-8000.
  • Several of the examples below show the effect of sulfoxide and hydroxyl containing compounds on the levels of amplification attainable with 2-enzyme 3SR or 3-enzyme 3SR.
  • RTs are AMV reverse transcriptase, recombinant MMLV reverse transcriptase and HIV-1 reverse transcriptase, which lack 5'-to-3' exonuclease activity.
  • the improved reaction media should be supplemented with a sulfoxide compound of the formula R 1 -(SO)-R 2 , wherein R 1 and R 2 are independently C 1 -C 4 alkyl and wherein R 1 and R 2 can be joined as part of a saturated cyclic moiety (preferably 10% dimethylsulfoxide (DMSO) by volume) where AMV reverse transcriptase is employed for 2-enzyme 3SR, but such a sulfoxide compound may be omitted where a reverse transcriptase derived from MMLV, HIV-1, or other retrovirus is utilized.
  • DMSO dimethylsulfoxide
  • the improved reaction media further improves amplification levels in 3SR reactions carried out in the presence of E. coli RNAse H.
  • DMSO or other sulfoxide containing compound may be used to increase amplification levels in such 3-enzyme 3SR reactions utilizing AMV reverse transcriptase.
  • reaction media should be supplemented with 0.1 - 10 mM MnCl 2 or similar manganese salt where MMLV reverse transcriptase is employed in the 2-enzyme 3SR reactions of the present invention.
  • concentration of rNTPs in the improved reaction media of the present invention should be most preferably about 6mM although lesser concentrations of rNTPs in the improved reaction media may be employed for 3-enzyme 3SR.
  • concentration of rNTPs in the improved reaction media of the present invention should be most preferably about 6mM although lesser concentrations of rNTPs in the improved reaction media may be employed for 3-enzyme 3SR.
  • concentration of rNTPs represents a large molar excess of substrate. Concentrations of rNTPs greater than about 8mM or 9mM tend to reduce the levels of amplification which may be obtained in two-enzyme 3SR reactions.
  • Example III below, demonstrates the capacity of an improved reaction medium of the invention, but not a prior art reaction medium reported to support 3-enzyme 3SR, to sustain 2-enzyme 3SR.
  • RNA polymerase 60-100 units
  • target segments longer than about 200 nucleotides in length may be more effectively amplified where the reaction medium is supplemented with about 1 to about 25 weight percent of an alcohol or polyhydroxy compound using either the 2-enzyme or 3-enzyme methods.
  • sugar alcohol of the formula HOCH 2 (CHOH) x CH 2 OH, wherein x is 0-20, more preferably, wherein x is 0-5, and most preferably where the compound is sorbitol or glycerol.
  • a preferred reaction medium of the present invention for carrying out 2-enzyme 3SR amplification is an aqueous solution comprising:
  • BUFFER Tris pH 8.1, 40 mM.
  • NUCLEOTIDES rNTPs, 6mM
  • 0.25 ⁇ g sense primer comprising a 15-base target binding region; and 0.25 ⁇ g antisense primer comprising a
  • ENZYMES AMV Reverse Transcriptase, 10 units/100 ⁇ l reaction solution
  • reaction solution comprising 10% dimethyl sulfoxide (DMSO) and 15% sorbitol
  • reaction solution comprising 1 mM MnCl 2 and 15% sorbitol
  • Temperature of the reaction mixture during 2-enzyme or 3-enzyme 3SR amplification also has a marked effect on the level of amplification achieved. While amplification may be carried out at temperatures between about 5°C and about 50°C, more preferably amplification is carried out at between about 37°C and about 47°C and most preferably at about 42oC. Reaction temperature is particularly important in the 2-enzyme 3SR methods of the present invention, with amplification at 42°C being approximately 100-fold more effective than at 37°C.
  • amplification rates are 2- to 3-fold greater in the 42°C - 45°C temperature range in the presence of an alcohol or polyhydroxyl-containing additive such as sorbitol, glycerol, ethanol and the like, and
  • DMSO or like sulfoxide compound where AMV reverse transcriptase is utilized.
  • the 3SR reaction may be more efficient in one amplification loop than in the other. Therefore, where both the sense and the antisense primers include a promoter encoding segment, either the sense or the antisense product may predominate, presumably because sequences downstream from the double stranded promoter segment of the cDNA may have a significant effect on transcription rates.
  • the present invention concerns DNA primers capable of priming a chain
  • primers comprise a promoter sense strand having at least one to ten nucleotides extending 5' from and adjoining the 5'-most nucleotide of the segment with the sense strand of the promoter's polymerase binding site (preferably with the sequence of the promoter's consensus sequence).
  • the inventors have surprisingly discovered that the length and sequence of the promoter-providing segment of a primer having a promoter sense strand has a marked affect on the level of amplification in 3SR. It has been found that primers truncated at their 5'-end with the 5'-nucleotide of the promoter consensus sequence (i.e., the 5'-end of the primer is the 5'-most nucleotide of the consensus
  • a promoter has a number of parts. First, it has a polymerase binding segment, which is the segment of double-stranded DNA to which the polymerase binds in initiating
  • a promoter must have at least a
  • the consensus sequence is the minimum sequence necessary, in completely double-stranded form, which is necessary for the binding of RNA polymerase in the process of initiating transcription.
  • the consensus sequence for the T7 promoter is disclosed herein.
  • Other promoter consensus sequences are
  • the sense strand of the T3 consensus sequence is 5'-ATTAACCCTCACTAAA-3' and the T3 transcription initiation sequence is 5'-GGGA-3'.
  • two versions of the SP6 promoter are well-known.
  • the consensus sequence of the sense strand of the SP6 promoter (version 1) is 5'-ATTTAGGTGACACTATA-3' and the consensus sequence of the sense strand of the SP6 promoter (version 2) is 5'-AATTAGGGGACACTATA-3'; the transcription initiation sequence for both version 1 and version 2 of the SP6 promoter is 5'-GAAG-3'.
  • the initial concentration of target segment is in the concentration range of about 0.01 - 1 attomole in a 100 ⁇ l aliquot - a concentration which is not unusual for detection of the presence of, for example, HIV-1 virus or a defective gene characteristic of a disease state - such a level of amplification is not detectable by standard nucleic acid hybridization assays.
  • concentration range of about 0.01 - 1 attomole in a 100 ⁇ l aliquot - a concentration which is not unusual for detection of the presence of, for example, HIV-1 virus or a defective gene characteristic of a disease state - such a level of amplification is not detectable by standard nucleic acid hybridization assays.
  • promoter-providing primers which have as few as 1
  • promoter consensus sequence surprisingly show about a 10-fold increase in amplification
  • oligonucleotide from its 5 '-end more than 4 nucleotides, and up to about 10 nucleotides, relative to a promoter consensus sequence may improve amplification over the level achieved with 1 to 4 nucleotides, as shown in the following Table.
  • 1/ Coding strand sequence is displayed.
  • the underlined sequence corresponds to the cannonical 17 nt T7-promoter sequence and the initiation of RNA transcription is denoted by +1.
  • the sequence GGGA is from the T7 sequence; the
  • +5 nucleotides onward is the HIV-1 sequence; subsequent sequences are identical for each oligonucleotide.
  • Olignonucleotides are aligned to display differences among the primers.
  • 2/ 3SR reactions were performed in 50 ⁇ l containing 0.05 attomoles ( ⁇ 1,000 molecules) of HIV-1 RNA target, 30U T7 RNA polymerase, 2u E. coli RNAseH, 15U AMV RT, 40mM Tris, pH 8.1, 30mM MgCl2, 20mM KCl, 10mM DTT, 4mM spermidine, 1mM dXTP,
  • RNA product made is 214 nucleotides long. Amplified targets were quantitated using beadbased sandwich hybridization (BBSH) employing
  • the promoter-containing primers of the present invention having 1-10 nucleotides, and preferably 1-4 nucleotides, adjoining the 5'-terminal nucleotide of the consensus sequence significantly enhance
  • the one to ten nucleotide sequence adjoining the 5'-end of the consensus sequence ensures that the reverse transcriptase remains associated with the DNA template strand at least until a cDNA having a completely double stranded promoter segment is completed.
  • an asterisk denotes a promoter-providing oligonucleotide primer comprising the segment 5 '-AATTTAATAC GACTCACTAT AGGGA-3' (SEQ ID NO: 15), wherein the underlined sequence is the 17-nucleotide consensus sequence of the promoter recognized by the T7 bacteriophage DNA-dependent RNA polymerase.
  • the 4 nt sequence (5'-AATT-3') at the 5'-end of the consensus sequence is defined herein to be
  • promoter sense strand and the 4 nt segment (e.g., 5'-GGGA-3' or 5'-GAAA-3', etc.) at the 3'-end of the consensus sequence is the T7
  • variable subsegment of the primer. Sequence corresponding to this variable subsegment will occur in transcripts made from the promoter corresponding to the promoter sense strand. For example, the
  • promoter-containing oligonucleotide probe designated 88-347 * consists of a segment which is the complement of the segment of the HIV-1 genome corresponding to
  • nucleotides 6661-6631 (inclusive) the 4 nt variable subsegment corresponding to the transcription initiation sequence 5'-GGGA-3', and the 21 nt promoter sense strand with the sequence given above, and has the following complete sequence:
  • primer # The nucleotide sequences of the following oligonucleotide primers (designated by primer #) are disclosed in
  • a designation of “sense” means that the primer comprises a segment with the same sequence as the indicated segment from the HIV-1 genome.
  • a designation of “Antisense” means that the primer comprises a segment that is complementary in sequence to the indicated segment from the HIV-1 genome.
  • the invention concerns methods useful for detection of at least one specific RNA target segment in a sample containing nucleic acid
  • RNA target segment comprising amplifying said RNA target segment according to the above-recited methods and detecting the presence of RNA transcripts which comprise a sequence that is the same as or complementary to that of said target segment. Detecting amplified nucleic acid products may be
  • Example II describes the bead-based sandwich hybridization technique, which is the preferred method for detecting amplification products.
  • detection methods are performing amplification using ribonucleoside triphosphates which have been labelled with a radioisotope, or a chromogenic or fluorescent substrate, or a group such as biotinyl, capable of being bound by a complex comprising an enzyme capable of catalyzing a chromogenic reaction, as well known in the art, and detecting the presence in a hybridization assay of RNA transcripts which have incorporated such labelled rNTPS.
  • the invention also entails kits for carrying out the amplification methods of the
  • kits of the invention may comprise one sense and one antisense primer (one or both including a
  • kits of the invention may include components for 3-enzyme 3SR, including an enzyme that provides RNAse H activity but is not a reverse transcriptase, and an aqueous solution to provide an improved reaction medium of the invention or compound (e.g., salts, buffers, hydroxy compounds, DMSO, nucleoside triphosphates) to prepare such an improved reaction medium.
  • 3-enzyme 3SR including an enzyme that provides RNAse H activity but is not a reverse transcriptase
  • an aqueous solution to provide an improved reaction medium of the invention or compound (e.g., salts, buffers, hydroxy compounds, DMSO, nucleoside triphosphates) to prepare such an improved reaction medium.
  • the invention also encompasses the improved reaction medium.
  • Methods and kits for carrying out nucleic acid hybridization probe assays may entail, in addition, steps and components necessary for detecting the RNA product resulting from amplification according to the invention.
  • the skilled understand the various additional steps and components, respectively, that are required to detect RNA from an amplification process by any of the numerous nucleic acid probe hybridization assay methods known in the art.
  • a 5'-aminohexyl phosphoramidate oligonucleotide derivative was prepared by reacting 5'-phosphorylated 88-297 (5'-TGGCCTAATTCCATGTGTACATTGTACTGT-3') (SEQ ID NO: 16) with 1,6 diaminohexane in the presence of 0.25 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in 0.1 M methylimidazole, pH 6.0, as previously described by Chu et al., Nucleic Acids Res. 11, 6513-6529 (1983). It is essential to carry out this reaction in freshly silanized Eppendorf tubes to prevent nonspecific adsorption of nucleic acids to the walls of the tubes. The amine derivative was isolated by precipitating twice with 5'-phosphorylated 88-297 (5'-TGGCCTAATTCCATGTGTACATTGTACTGT-3') (SEQ ID NO: 16) with 1,6 diaminohexane in the presence of
  • N,N-dimethylformamide was added to 2.5 nmol of
  • Trisacryl-sulphydryl was carried out by first equilibrating the beads (10 g wet weight) with 0.5 M NaHCO 3 , pH 9.7. The volume was adjusted to 40 ml in a 50-ml
  • the beads were then equilibrated in 50 ml 0.1 M Tris, pH 8.5, to hydrolyze the thioester linkages. After 1 h, the support was washed with TE, pH 8.0, and stored at 4oC. The sulphydryl group concentration in the support was estimated by titrating with 5,5'-dithiobis(2-nitrobenzoic acid) and monitoring the release of 3-carboxylate-4-nitrothiophenolate at 412 nm. Finally, the covalent attachment of
  • Trisacryl-sulphydryl support (1 g), obtained from the above reaction, was reduced with 30 ml 20 mM DTT in 0.05 M K 2 HPO 4 , pH 8.0, and 1 mM EDTA for 1 h. The support was then washed four times with 25 ml of 0.05 M K 2 HPO 4 , pH 8.0, 1 mM EDTA, followed by two washes with 25 ml of 0.1 M triethylammonium phosphate (TEAP), 1 mM EDTA, pH 9.0. Five nanomoles of bromoacetyl- derivatized
  • the beads were washed twice with 35 ml of 0.1 M Tris, pH 8.0, 0.1 M NaCl, 1 mM EDTA, and 0.1% SDS, four times with 45 ml of 0.1 M Na 2 P 2 O 7 , pH 7.5, followed by two washes with 45 ml of TE, pH 8.0, and stored at 4oC.
  • Nucleic acids from 2.5 ⁇ 10 5 PBMC from both normal patients and patients with cystic fibrosis were extracted as in Example 1.
  • the precipitated nucleic acids were pelleted by ⁇ entrifugation. The pellet was drained, rinsed with 70% ethanol one time, dried and then
  • AMV reverse transcriptase (RT) (Life Science, Inc.) were added. The samples were incubated at 42°C for 15 minutes then heated to 100°C for 1 minute. Thirty units of AMV RT, 100 units T7 RNA polymerase (Stratagene) and 4 units E. coli Rnase H (Bethesda Research Labs) were added. The samples were incubated at 42°C. for 1 hour. The samples were then frozen at -20°C. The samples were then analyzed by bead-based sandwich hybridization using OligobeadsTM
  • BBSH BBSH
  • 2S-GS 2 ml micro-column
  • the target in 20 ⁇ l of TE, is added to the column, along with 10 ⁇ l of 2x hybridization solution (20% dextran sulfate, 20x SSPE, 0.2% SDS) which had been warmed to 42°C.
  • the micro-columns are vortexed and incubated with occasional agitation at 42°C for two hours.
  • the beads are washed six times with 1ml each of 2x SSC which had been equilibrated at 42°C. Cerenkov counting of the columns and washes is used to determine the amount of target detected. Counter background is subtracted from all samples and the fm of target detected is calculated as follows:
  • 0.1 attomoles of HIV-1 RNA was amplified in 2-enzyme 3SR or 3-enzyme 3SR reactions at 37°C under prior art reaction conditions and under improved reaction conditions of the invention. Under improved conditions, but not under prior art conditions, 2-enzyme 3SR
  • Each reaction solution contained 0.25 ⁇ g each of oligonucleotide primers 88-211 * and 88-347 * , 10 units AMV reverse transcriptase and 20 units T7 RNA polymerase. Total reaction volume was 100 ⁇ l. A "+" in the
  • RNAse H column denotes the presence of 4 U E. coli RNAse H in the reaction medium, while a “+” in the “DMSO/PEG-8000” column denotes that the reaction medium was supplemented with 10%
  • reaction products were detected by bead-based sandwich hybridization (Example II) using OligobeadsTM derivatized with oligonucleotide #86-273 and
  • Glycerol and/or 5% polyethylene glycol (PEG-8000) on the level of amplification obtainable in 2-enzyme or 3-enzyme 3SR reactions.
  • reaction conditions used for the 3SR reactions were the same as the "Preferred 3SR Reaction Medium" disclosed in Example III except that reactions were carried out at 42°C for 1 hour.
  • the 3SR reactions were carried out using 0.1 attomoles HIV-1 RNA as target and the primer pair
  • oligonucleotide 87-81 as probe.
  • enhanced levels of amplification are obtained in the presence of 10% DMSO and 10% glycerol.
  • MMLV reverse transcriptases from Moloney murine leukemia virus (MMLV), HIV-1 and avian myeloblastosis virus (AMV).
  • MMLV reverse transcriptase has a requirement for
  • transcriptase 100 Units T7 DNA-dependent RNA polymerase, 4 Units RNAse H, at 42° C for 1 hour in the preferred reaction medium disclosed in Example III using one of the following sets of env primer pairs: 88-211 * /88-347 * or 87-79/88-347 * .
  • This example shows the effect of nucleotide alterations at 5' and 3' ends of oligonucleotide primers containing the consensus sequence of the T7 promoter.
  • RNA product made is 214 nucleotides long.
  • BBSH beadbased sandwich hybridization
  • AATTTAATACGACTCACTATA TGTACTATTATGGTTTTAGCATTGTCTGTGA 2.8 ⁇ 10 9 1/ Coding strand sequence is displayed.
  • the underlined sequence corresponds to the cannonical 17 nt T7-pretnoter sequence and the initiation of RNA transcription is denoted by +1.
  • the sequence GGGA is from the T7 sequence; the +5 nucleotides onward is the HIV-1 sequence. Only the 5' end portion of each oligonucleotide is presented; subsequent sequences are identical for each oligonucleotide. Olignonucleotides are aligned to display differences among the primers.
  • This example demonstrates the effect of various combinations of additives on the amplification of a 707-base region of the pol gene from HIV-1. Reactions were performed at 42°C for two hours with 0.1 attomoles of HIV-1 RNA as the target and 90-249 (sense)
  • the probe and OligobeadTM sequences were 89-534 5'-AGGATCTGACTTAGAAATAGGGCAGCA-3' (SEQ ID NO: 32) and 89-419 5'-AGAACTCAAGACTTCTGGGAAGTTC-3' (SEQ ID NO: 32) and 89-419 5'-AGAACTCAAGACTTCTGGGAAGTTC-3' (SEQ ID NO: 32) and 89-419 5'-AGAACTCAAGACTTCTGGGAAGTTC-3' (SEQ ID NO: 32) and 89-419 5'-AGAACTCAAGACTTCTGGGAAGTTC-3' (SEQ ID NO: 32) and 89-419 5'-AGAACTCAAGACTTCTGGGAAGTTC-3' (SEQ ID NO: 32) and 89-419 5'-AGAACTCAAGACTTCTGGGAAGTTC-3' (SEQ ID NO: 32) and 89-419 5'-AGAACTCAAGACTTCTGGGAAGTTC-3' (SEQ ID NO: 32)
  • MOLECULE TYPE DNA (genomic)
  • POSITION IN GENOME GENOME
  • MDLECDLE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • GATTTAATAC GACTCACTAT AGGGATGTAC TATTATGGTT TTAGCATTGT CTGTGA 56
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE T ⁇ EE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Nouveaux procédés d'amplification d'acides nucléiques par réplication continue auto-entretenue, essentiellement isothermique, de séquences ("3SR") exploitant l'activité d'ADN polymérase dépendant de l'ARN, l'activité d'ADN polymérase dépendant de l'ADN, l'activité d'ARNase H et l'activité d'ARN polymérase dépendant de l'ADN. Dans l'un des procédés, des activité enzymatiques sont assurées par uniquement deux enzymes, une transcriptase inverse et une ARN polymérase dépendant d'ADN. Ces procédés peuvent employer deux ou trois enzymes qui assurent les activités enzymatiques nécessaires. On emploie ainsi, dans certains procédés, une source exogène d'ARNase H, telle que l'ARNase H d'E. coli, en combinaison avec une transcriptase inverse et une ARN polymérase dépendant d'ADN. Dans d'autres procédés de la présente invention, on utilise des milieux de réaction dans lesquels l'activité d'ARNase H inhérente des transcriptases inverses rétrovirales permet d'atteindre des niveaux élevés d'amplification, de sorte qu'uniquement deux enzymes, à savoir une transcriptase inverse et une ARN polymérase dépendant d'ADN, sont nécessaires. On décrit également de nouvelles compositions permettant d'exécuter les procédés de la présente invention.
EP19920901557 1990-11-13 1991-11-13 Amplification d'acides nucleiques par replication bi-enzymatique auto-entretenue de sequences. Ceased EP0572417A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61268890A 1990-11-13 1990-11-13
US612688 1990-11-13
PCT/US1991/008488 WO1992008800A1 (fr) 1990-11-13 1991-11-13 Amplification d'acides nucleiques par replication bi-enzymatique auto-entretenue de sequences

Publications (2)

Publication Number Publication Date
EP0572417A1 true EP0572417A1 (fr) 1993-12-08
EP0572417A4 EP0572417A4 (fr) 1994-11-23

Family

ID=24454235

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920901557 Ceased EP0572417A4 (fr) 1990-11-13 1991-11-13 Amplification d'acides nucleiques par replication bi-enzymatique auto-entretenue de sequences.

Country Status (13)

Country Link
EP (1) EP0572417A4 (fr)
JP (1) JPH06502767A (fr)
AU (1) AU9131591A (fr)
CA (1) CA2096013A1 (fr)
FI (1) FI932144A (fr)
HU (1) HUT69772A (fr)
IE (1) IE913930A1 (fr)
IL (1) IL100040A (fr)
NO (1) NO931709L (fr)
NZ (1) NZ240574A (fr)
PT (1) PT99500A (fr)
WO (1) WO1992008800A1 (fr)
ZA (1) ZA918965B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628076A1 (fr) * 1992-11-19 1994-12-14 GINGERAS, Thomas R. PRODUCTION D'ANTICORPS MONOCLONAUX RECOMBINES SANS UTILISATION D'HYBRIDOMES ET PAR CULTURE $i(IN VITRO) DE FRAGMENT DE RATE COMBINEE AVEC LA REPLICATION AUTONOME ISOTHERMIQUE DE SEQUENCES D'ARN
EP0682121B1 (fr) * 1993-12-01 2002-08-28 Toyo Boseki Kabushiki Kaisha Procede d'amplification et de detection d'une sequence nucleotidique au moyen d'enzymes thermostables
US5705366A (en) * 1994-09-15 1998-01-06 Johnson & Johnson Clinical Diagnostics, Inc. Coamplification of target nucleic acids using volume exclusion agent in reaction composition, test kit and test device useful therefor
JPH08131171A (ja) * 1994-11-11 1996-05-28 Asahi Chem Ind Co Ltd 逆転写酵素の安定化組成物
US5763184A (en) 1996-01-30 1998-06-09 Roche Molecular Systems, Inc. Nucleotide sequence variation in the ABO glycosyltransferase gene
WO2000000638A2 (fr) * 1998-06-26 2000-01-06 Akzo Nobel N.V. Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription
JP2001029078A (ja) * 1999-07-16 2001-02-06 Shimadzu Corp Ｒｎａ増幅法
WO2002012263A1 (fr) 2000-08-03 2002-02-14 Roche Diagnostics Gmbh Composes de fixation d'acides nucleiques contenant des analogues pyrazolo[3,4-d]pyrimidine de purine 2,6-diamine et leurs utilisations
US6780588B2 (en) 2001-05-07 2004-08-24 Applera Corporation Methods for the reduction of stutter in microsatellite amplification
US6841349B2 (en) 2001-05-07 2005-01-11 Applera Corporation Applied Biosystems Group Methods for the reduction of stutter in microsatellite amplification
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US9777312B2 (en) 2001-06-30 2017-10-03 Enzo Life Sciences, Inc. Dual polarity analysis of nucleic acids
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
WO2003057910A2 (fr) 2002-01-08 2003-07-17 Roche Diagnostics Gmbh Utilisation d'un materiau de silice dans une reaction d'amplification
US7122314B2 (en) 2002-01-30 2006-10-17 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes
DE10240868A1 (de) * 2002-09-04 2004-03-18 Artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH Verbesserte Verfahren zur Synthese von Nukleinsäuren
DE602004009038T3 (de) 2003-01-29 2015-06-25 Roche Diagnostics Gmbh Verbessertes Verfahren zur Behandlung durch Bisulfit
JP2004357502A (ja) * 2003-05-30 2004-12-24 Olympus Corp 核酸分子を使用した情報処理方法
WO2006006722A1 (fr) 2004-07-13 2006-01-19 Takeda Pharmaceutical Company Limited Méthode de contrôle des fonctions d’une cellule
EP1632578A1 (fr) 2004-09-03 2006-03-08 Roche Diagnostics GmbH Méthode pour la décontamination de l' ADN
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
AU2008283902B2 (en) 2007-08-06 2014-03-13 Orion Genomics Llc Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
CA2639416C (fr) 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Test de diagnostic pour la susceptibilite aux inhibiteurs de la b-raf kinase
AU2008318316B2 (en) 2007-11-01 2015-08-06 University Of Iowa Research Foundation RCA locus analysis to assess susceptibility to AMD and MPGNII
EP2396429B1 (fr) 2009-02-11 2015-05-27 Orion Genomics, LLC Combinaisons de polymorphismes destinées à déterminer l'expression spécifique des allèles d'igf2
WO2011128096A1 (fr) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Marqueurs de polymorphisme destinés à prédire la réponse à un traitement par un médicament anticorps monoclonal inhibant les récepteurs de l'interleukine-6
US20130143214A1 (en) 2010-06-04 2013-06-06 Chronix Biomedical Prostate cancer associated circulating nucleic acid biomarkers
US20140004510A1 (en) 2010-09-24 2014-01-02 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
US9458484B2 (en) 2010-10-22 2016-10-04 Bio-Rad Laboratories, Inc. Reverse transcriptase mixtures with improved storage stability
EP2751280B1 (fr) 2011-08-31 2016-06-29 F.Hoffmann-La Roche Ag Procédé de prédiction du risque d'hypertension associée à une thérapie anti-angiogenèse
WO2013030167A1 (fr) 2011-08-31 2013-03-07 F. Hoffmann-La Roche Ag Réactivité aux inhibiteurs de l'angiogenèse
KR20140064971A (ko) 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
US20140303008A1 (en) 2011-10-21 2014-10-09 Chronix Biomedical Colorectal cancer associated circulating nucleic acid biomarkers
EP2783015A1 (fr) 2011-11-23 2014-10-01 F.Hoffmann-La Roche Ag Sensibilité aux inhibiteurs de l'angiogenèse
US9115394B2 (en) 2011-12-22 2015-08-25 Roche Molecular Systems, Inc. Methods and reagents for reducing non-specific amplification
US20160115541A1 (en) 2013-05-29 2016-04-28 Chronix Biomedical Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients
KR20160138494A (ko) 2014-03-31 2016-12-05 데비오팜 인터네셔날 에스 에이 Fgfr 융합물
US20160168640A1 (en) 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
ES2961374T3 (es) 2015-04-24 2024-03-11 Atila Biosystems Incorporated Amplificación con cebadores de composición de nucleótidos limitada
PT3640345T (pt) 2015-08-17 2021-12-29 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
DK3534885T3 (da) 2016-11-03 2021-04-12 Kura Oncology Inc Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
EP3432883B1 (fr) 2017-02-21 2021-07-28 Kura Oncology, Inc. Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MY200746A (en) 2017-08-07 2024-01-13 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20230142806A (ko) 2018-02-09 2023-10-11 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
CA3117968A1 (fr) 2018-11-01 2020-05-07 Kura Oncology, Inc. Methodes de traitement du cancer avec des inhibiteurs de la farnesyltransferase
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CN113795253A (zh) 2019-03-29 2021-12-14 库拉肿瘤学公司 用法呢基转移酶抑制剂治疗鳞状细胞癌的方法
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
WO2024015331A1 (fr) 2022-07-12 2024-01-18 Genentech, Inc. Méthodes thérapeutiques et diagnostiques pour la sclérose en plaques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0408295B1 (fr) * 1989-07-11 1996-08-28 Gen-Probe Incorporated Méthodes pour l'amplification de séquences d'acide nucléique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
CA1340807C (fr) * 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
ZA899593B (en) * 1988-12-16 1990-09-26 Siska Diagnostics Inc Self-sustained,sequence replication system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0408295B1 (fr) * 1989-07-11 1996-08-28 Gen-Probe Incorporated Méthodes pour l'amplification de séquences d'acide nucléique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9208800A1 *

Also Published As

Publication number Publication date
WO1992008800A1 (fr) 1992-05-29
IL100040A (en) 1995-12-31
HU9301369D0 (en) 1993-10-28
FI932144A0 (fi) 1993-05-12
NO931709D0 (no) 1993-05-11
JPH06502767A (ja) 1994-03-31
PT99500A (pt) 1992-10-30
ZA918965B (en) 1992-08-26
IL100040A0 (en) 1992-08-18
IE913930A1 (en) 1992-06-17
NO931709L (no) 1993-07-12
EP0572417A4 (fr) 1994-11-23
NZ240574A (en) 1994-10-26
AU9131591A (en) 1992-06-11
FI932144A (fi) 1993-05-12
CA2096013A1 (fr) 1992-05-14
HUT69772A (en) 1995-09-28

Similar Documents

Publication Publication Date Title
EP0572417A1 (fr) Amplification d'acides nucleiques par replication bi-enzymatique auto-entretenue de sequences
CA2497420C (fr) Compositions ameliorees et methodes de synthese de l'adnc
JP2648802B2 (ja) 増強された核酸増幅方法
EP2464755B1 (fr) Procédés et kits de marquage de l'extrémité 3' de l'arn
CA2707436C (fr) Adn de copie et arn sens
CA2577122C (fr) Techniques d'amplification d'acide nucleique avec une seule amorce
EP2867366B1 (fr) Procédé pour l'amplification isotherme d'adn à partir de l'arn dans un seul mélange réactionnel
KR20160034305A (ko) 리가제-연관 핵산 원형화 및 증폭
EP1546313B1 (fr) Ligase d'arn thermostable provenant d'un bacteriophage thermus
AU759915B2 (en) Reversible inhibiting probes
EP1546355B1 (fr) Procedes d'utilisation de ligases d'arn thermostables
US20140004509A1 (en) Kit for isothermal dna amplification starting from an rna template

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930608

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19941004

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960517

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AKZO NOBEL N.V.

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20000519